Aimaz Afrough

#ASH25 not many investigator meetings look like this, but the @CoMMitTrials meeting thanks to @End_myeloma! 🍷 not shown, nor the 🛩️ Luciano has earned. Look for many innovative trial results coming soon, including MASTER-2 with MRD-guided decision-making!

#ASH25 @ASH_hematology Meeting fellowship family @BCMHemeOnc @bcmhouston @Sarasinh @AimazAfrough @mahrefat @marthamims Lots of myeloma in one pic #mmsm

#mmsm #ASH25 🙏 to all members of the US MM immunotherapy consortium @StanfordDeptMed @StanfordBMT_CT @MoffittNews @VincentRK @End_myeloma @OmarNadeemMD @cjferreriMD @ldandersonjr @AimazAfrough

Study now open @UTSWMedCenter. Patients newly diagnosed with MM in the Dallas area can receive personalized response-adapted treatment with the wonderful @ldandersonjr @AimazAfrough @HealthTree #MMSM @utswcancer

#Myeloma Paper of the Day: Comparison of standard-of-care Ide-cel and Cilta-cel in relapsed/refractory myeloma finds Cilta associated w/ higher likelihood of grade ≥3 CRS, SPMs, and delayed neurotox, but better treatment responses, PFS, and OS: pubmed.ncbi.nlm.nih.gov/39965175/. #mmsm

#Myeloma Paper of the Day: Whole genome sequencing of extramedullary disease in myeloma finds BRAF, NRAS, KRAS & MYC frequently implicated oncogenes, w/ frequent loss of tumor suppressor genes SP140 & TENT5C, suggesting central role of MAPK pathway: pubmed.ncbi.nlm.nih.gov/39799110/. #mmsm

Why? Excellent #IMS24 plenary by Machlachlan @MSKCancerCenter 👇 PMD and EMD look very different at a genomic level, and we should stop conflating them. Kudos to many junior faculty @ZanwarSaurabh @DimaDanai @AimazAfrough @DarrenPanMD et al who’ve helped show this clinically!

CONGRESS | #IMS2024 | PRESENTATION Meletios Dimopoulos @thanosdimop shares findings from a cytogenetic risk analysis of the phase III PERSEUS trial (N = 709), which demonstrated a significant PFS benefit for the addition of daratumumab (D) to VRd induction and consolidation therapy and to lenalidomide maintenance therapy for transplant eligible (TE) patients with NDMM. This analysis confirmed the favorable PFS benefits and demonstrated the higher rates of deep and sustained MRD negativity with the addition of D to VRd induction and R maintenance, supporting the use of D-VRd induction/consolidation followed by D-R maintenance as a new SOC for TE NDMM. Follow our live feed for more updates: multiplemyelomahub.com/medical-inform… #mmsm #myeloma #MedicalCongress

#IMS24 the US #MMsm immunotherapy consortium is growing and I could not be happier to see it! @SurbhiSidanaMD @DrKrinaPatel @bhemato @PlasmaCellPete @ldandersonjr @BiranNoa @khouri_jack @AimazAfrough - missing @AlGarfall @GKaurMD and many more!

Looking forward to this discussion with these outstanding colleagues #SOHO2024 #bmtsm #MDS #leusm

Instagram Post 📢 Big News! We are thrilled to announce that @SuzanneColeMD has been selected as one of the recipients of the 2023-2024 IM UME Outstanding Faculty Teaching Award! 🏆✨ @UTSWInternalMed @utswcancer

Happening now, poster P939 #EHA24. Love to hear your feedback. #CIBMTR

Out now in Journal of Hematology and Oncology: Impact of Extramedullary Multiple Myeloma on Outcomes with Ide-cel: jhoonline.biomedcentral.com/articles/10.11… @myelomaMD @YiLinMDPhD @DrKrinaPatel @SurbhiSidanaMD #dorishansen @MoffittNews @BioMedCentral Top line results and a brief 🧵 1/

Congrats to Dr. Saurabh Zanwar, Dr. Doris Hansen and the US Myeloma Immunotherapy Consortium for another great paper! Largest cohort evaluated to date for outcomes on EMD and PMD, both high risk factors for RRMM #mmsm @MayoClinic @MoffittNews link.springer.com/10.1186/s13045…

#ASCO24 DREAMM-7 Bela-Vd vs. Dara-Vd for RRMM. >/=2nd line. N=494, median F/U: 28.2 months. Median PFS 36.6 vs. 13.4 months favoring Bela-Vd (HR=0.41). More ocular AEs with Bela-Vd, improved with dose modifications #mmsm @dra_v_hungria @mvmateos @NEJM nejm.org/doi/full/10.10…

Absolutely mind-blowing talk today by the brilliant @DiPersioLab, visiting @utswcancer! On CART-cell therapy for #T-ALL, epitome of #BenchToBedside innovation! “EVERYONE is an expert and everyone has unproven approaches that become almost Mythical over time”. 😂🎉@UTSWHemeOnc

Nobel laureate @kaelin_lab gave a special @UTSWInternalMed grand rounds this AM during the #SeldinSymposium — his journey from @DukeMedSchool to @HopkinsMedicine & @harvardmed @DanaFarber & discoveries for anemia, ischemia, & #kidneycancer along the way. @utswcancer

Natalie S. Callander, MD, on Multiple Myeloma: Management Updates ascopost.com/videos/2024-nc… #mmsm #MultipleMyeloma @nsc_natalie @UWCarbone #hematology #guidelines #NCCN2024 @NCCN

Nobel laureate Dr. William Kaelin delivers the Seldin Symposium keynote address to a packed house! ⁦@UTSWMedCenter⁩ ⁦@thomasjwang1⁩ ⁦@UTSWIMchief⁩ #SeldinSymposium2024

And excellent #MMsm editorial by @JoshuaRichterMD! When we need a bridge over troubled water (well played), use alkylators but don’t overuse them. Plus an intriguing nod to GPRC5D bsAbs as bridging before BCMA CAR-T… Science at work! nature.com/articles/s4140…